Overview

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Status:
RECRUITING

Trial end date:
2032-01-11

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).

Phase:

PHASE4

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

ruxolitinib